Neuroimaging has revolutionized the diagnosis, monitoring, and understanding of [neurodegenerative diseases]. From structural magnetic resonance imaging (MRI) that reveals patterns of brain atrophy, to molecular positron emission tomography (PET) that visualizes specific proteinopathies in vivo, imaging technologies provide critical biomarkers for clinical diagnosis, research, and therapeutic development. The integration of neuroimaging into diagnostic frameworks — including the 2024 revised [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX-- criteria — underscores its central role in modern neurology 1(https://pubmed.ncbi.nlm.nih.gov/39483064/).
Neuroimaging modalities can be broadly divided into structural imaging (MRI, CT), functional imaging (fMRI, SPECT), and molecular imaging (PET with amyloid, tau, and dopamine tracers). Each modality provides complementary information about brain structure, function, and molecular pathology, enabling clinicians and researchers to track disease progression, differentiate between overlapping clinical syndromes, and evaluate therapeutic responses.
Structural MRI uses strong magnetic fields and radiofrequency pulses to generate high-resolution images of brain anatomy. Key sequences used in neurodegeneration include:
Each [neurodegenerative disease] exhibits characteristic patterns of brain atrophy on MRI:
[Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--: Medial temporal lobe atrophy, particularly of the [hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus--TEMP--/brain-regions)--FIX-- and [entorhinal [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX--, is the hallmark finding. The Scheltens visual rating scale grades hippocampal atrophy from 0 (normal) to 4 (severe). Posterior cortical atrophy predominates in the [posterior cortical atrophy (PCA)[/diseases/[posterior-cortical-atrophy[/diseases/[posterior-cortical-atrophy[/diseases/[posterior-cortical-atrophy--TEMP--/diseases)--FIX-- variant, while asymmetric left temporal atrophy characterizes [primary progressive aphasia (PPA)[/diseases/[primary-progressive-aphasia[/diseases/[primary-progressive-aphasia[/diseases/[primary-progressive-aphasia--TEMP--/diseases)--FIX-- 2(https://pubmed.ncbi.nlm.nih.gov/37872430/).
[Frontotemporal Dementia (FTD)[/diseases/[ftd[/diseases/[ftd[/diseases/[ftd--TEMP--/diseases)--FIX--: The behavioral variant shows frontal and anterior temporal atrophy, often asymmetric. Semantic variant PPA demonstrates anterior temporal pole atrophy (left > right), while nonfluent variant PPA shows left inferior frontal and insular atrophy 3(https://pubmed.ncbi.nlm.nih.gov/32129844/).
[Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX--: Subtle cortical thinning and subcortical volume loss in the [substantia nigra[/brain-regions/[substantia-nigra[/brain-regions/[substantia-nigra[/brain-regions/[substantia-nigra--TEMP--/brain-regions)--FIX-- and [striatum[/brain-regions/[striatum[/brain-regions/[striatum[/brain-regions/[striatum--TEMP--/brain-regions)--FIX--. Nigrosome-1 loss of the dorsolateral [substantia nigra[/brain-regions/[substantia-nigra[/brain-regions/[substantia-nigra[/brain-regions/[substantia-nigra--TEMP--/brain-regions)--FIX-- on susceptibility-weighted imaging ("swallow tail sign" loss) can support diagnosis 4(https://pubmed.ncbi.nlm.nih.gov/31629653/).
[Huntington's disease[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway--TEMP--/mechanisms)--FIX--: Caudate nucleus and [striatum[/brain-regions/[striatum[/brain-regions/[striatum[/brain-regions/[striatum--TEMP--/brain-regions)--FIX-- atrophy are early and prominent, with cortical thinning following as the disease progresses.
[Amyotrophic Lateral Sclerosis (ALS)[/diseases/[als[/diseases/[als[/diseases/[als--TEMP--/diseases)--FIX--: Upper motor neuron degeneration manifests as precentral gyrus atrophy. DTI reveals corticospinal tract degeneration with reduced fractional anisotropy.
[Multiple System Atrophy (MSA)[/diseases/[multiple-system-atrophy[/diseases/[multiple-system-atrophy[/diseases/[multiple-system-atrophy--TEMP--/diseases)--FIX--: The "hot cross bun sign" in the pons (MSA-C) and putaminal atrophy with a rim of T2 hyperintensity (MSA-P) are characteristic findings.
[Progressive Supranuclear Palsy (PSP)[/diseases/[progressive-supranuclear-palsy[/diseases/[progressive-supranuclear-palsy[/diseases/[progressive-supranuclear-palsy--TEMP--/diseases)--FIX--: Midbrain atrophy produces the "hummingbird sign" on sagittal view. The midbrain-to-pons ratio is reduced.
[Corticobasal Degeneration (CBD)[/diseases/[corticobasal-degeneration[/diseases/[corticobasal-degeneration[/diseases/[corticobasal-degeneration--TEMP--/diseases)--FIX--: Asymmetric frontoparietal cortical atrophy contralateral to the clinically more affected side.
Automated volumetric analysis using tools like FreeSurfer, FSL, and ANTs enables precise quantification of regional brain volumes. Longitudinal volumetric MRI is used in clinical trials to measure rates of whole-brain atrophy and regional volume loss as endpoints. The Alzheimer's Disease Neuroimaging Initiative (ADNI) has been instrumental in standardizing MRI protocols and establishing normative data for brain volumetrics across the Alzheimer's continuum 5(https://pubmed.ncbi.nlm.nih.gov/39711072/).
[amyloid PET[/entities/[amyloid-pet[/entities/[amyloid-pet[/entities/[amyloid-pet--TEMP--/entities)--FIX-- imaging detects fibrillar [amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- ([Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- deposits in the brain using radioligands that bind to [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- plaques. Approved tracers include:
[amyloid PET[/entities/[amyloid-pet[/entities/[amyloid-pet[/entities/[amyloid-pet--TEMP--/entities)--FIX-- is positive 15-20 years before symptom onset in [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--, making it valuable for identifying presymptomatic individuals and enriching clinical trials. [Amyloid] positivity is now a requirement for enrollment in anti-amyloid therapeutic trials, such as those for [lecanemab[/treatments/[lecanemab[/treatments/[lecanemab[/treatments/[lecanemab--TEMP--/treatments)--FIX-- and [donanemab[/treatments/[donanemab[/treatments/[donanemab[/treatments/[donanemab--TEMP--/treatments)--FIX--. [Amyloid-related imaging abnormalities (ARIA)[/diagnostics/[aria[/diagnostics/[aria[/diagnostics/[aria--TEMP--/diagnostics)--FIX-- monitoring during anti-amyloid therapy also relies on neuroimaging 6(https://pubmed.ncbi.nlm.nih.gov/37698424/).
[Tau[/entities/[tau-protein[/entities/[tau-protein[/entities/[tau-protein--TEMP--/entities)--FIX-- PET tracers bind to [neurofibrillary tangles[/mechanisms/[neurofibrillary-tangles[/mechanisms/[neurofibrillary-tangles[/mechanisms/[neurofibrillary-tangles--TEMP--/mechanisms)--FIX-- composed of hyperphosphorylated tau protein]. The most widely used second-generation tracer is [¹⁸F]MK-6240, along with [¹⁸F]PI-2620, [¹⁸F]GTP1, and [¹⁸F]flortaucipir (Tauvid) — the first FDA-approved tau PET tracer.
Tau PET signal correlates closely with cognitive decline and neurodegeneration in Alzheimer's Disease, often more strongly than amyloid PET. Tau PET staging follows [Braak staging[/mechanisms/[braak-staging[/mechanisms/[braak-staging[/mechanisms/[braak-staging--TEMP--/mechanisms)--FIX-- patterns, with early binding in the medial temporal lobe (Braak stages I-II) progressing to lateral temporal, parietal, and frontal cortices 7(https://pubmed.ncbi.nlm.nih.gov/40922096/).
Challenges remain in tau PET imaging for non-AD tauopathies ([PSP[/diseases/[psp[/diseases/[psp[/diseases/[psp--TEMP--/diseases)--FIX--, [CBD[/diseases/[corticobasal-degeneration[/diseases/[corticobasal-degeneration[/diseases/[corticobasal-degeneration--TEMP--/diseases)--FIX--, [Pick's disease), as current tracers have lower affinity for 4R tau isoforms and straight filaments.
[¹⁸F]Fluorodeoxyglucose (FDG) PET measures regional cerebral glucose metabolism, which serves as a proxy for synaptic activity and neuronal function. Disease-specific hypometabolic patterns include:
FDG-PET is particularly useful for differentiating between neurodegenerative dementias when clinical presentation is atypical.
Dopamine transporter (DaT) SPECT using [¹²³I]ioflupane (DaTscan) or PET with [¹⁸F]DOPA visualizes presynaptic dopaminergic terminal integrity in the [striatum[/brain-regions/[striatum[/brain-regions/[striatum[/brain-regions/[striatum--TEMP--/brain-regions)--FIX--. Reduced uptake in the putamen is characteristic of neurodegenerative parkinsonism ([Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX--, [MSA[/diseases/[msa[/diseases/[msa[/diseases/[msa--TEMP--/diseases)--FIX--, [PSP[/diseases/[psp[/diseases/[psp[/diseases/[psp--TEMP--/diseases)--FIX--, [CBD), distinguishing these from essential tremor, drug-induced parkinsonism, and psychogenic movement disorders. DaT imaging does not differentiate between the different parkinsonian syndromes.
Translocator protein (TSPO) PET tracers, such as [¹¹C]PK11195 and second-generation tracers ([¹¹C]PBR28, [¹⁸F]DPA-714), detect activated [microglia[/entities/[microglia[/entities/[microglia[/entities/[microglia--TEMP--/entities)--FIX--
Resting-state fMRI (rs-fMRI) measures spontaneous low-frequency fluctuations in blood-oxygen-level-dependent (BOLD) signal to map functional brain networks without task demands. Key findings in neurodegeneration include:
Task-based fMRI paradigms, including memory encoding, executive function, and language tasks, reveal disease-specific patterns of hypoactivation and compensatory hyperactivation. These are primarily used in research settings.
While largely supplanted by MRI in neurodegenerative disease evaluation, CT remains useful for:
Beyond DaT imaging, perfusion SPECT using [⁹⁹ᵐTc]HMPAO or [⁹⁹ᵐTc]ECD measures regional cerebral blood flow. Perfusion SPECT shows patterns similar to FDG-PET (temporoparietal hypoperfusion in AD, frontal hypoperfusion in FTD) but with lower spatial resolution. Cardiac [¹²³I]MIBG scintigraphy demonstrating reduced postganglionic sympathetic innervation supports the diagnosis of [Lewy body dementia[/diseases/[lewy-body-dementia[/diseases/[lewy-body-dementia[/diseases/[lewy-body-dementia--TEMP--/diseases)--FIX-- and [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX--.
Machine learning and deep learning approaches are increasingly applied to neuroimaging data for automated diagnosis, prediction of disease progression, and identification of novel imaging biomarkers. Convolutional neural networks (CNNs) trained on structural MRI can classify Alzheimer's Disease with high accuracy, and multi-modal AI models integrating MRI, PET, and clinical data show promise for precision medicine approaches 10(https://pubmed.ncbi.nlm.nih.gov/39293530/).
7-Tesla MRI provides superior spatial resolution, enabling visualization of hippocampal subfields, cortical layers, and submillimeter brainstem structures. This is particularly valuable for research into [selective neuronal vulnerability[/mechanisms/[selective-neuronal-vulnerability[/mechanisms/[selective-neuronal-vulnerability[/mechanisms/[selective-neuronal-vulnerability--TEMP--/mechanisms)--FIX-- and early microstructural changes.
MRS measures brain metabolite concentrations non-invasively, including N-acetylaspartate (NAA, a marker of neuronal integrity), myo-inositol (a marker of gliosis), and glutamate/glutamine. Reduced NAA/creatine ratios and elevated myo-inositol are found in neurodegenerative diseases.
QSM quantifies tissue magnetic susceptibility, providing sensitive measures of iron deposition in the [basal ganglia[/brain-regions/[basal-ganglia[/brain-regions/[basal-ganglia[/brain-regions/[basal-ganglia--TEMP--/brain-regions)--FIX-- and [substantia nigra[/brain-regions/[substantia-nigra[/brain-regions/[substantia-nigra[/brain-regions/[substantia-nigra--TEMP--/brain-regions)--FIX--. This technique is valuable in [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX--, [Huntington's disease[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway--TEMP--/mechanisms)--FIX--, and [NBIA disorders].
The 2024 International Working Group (IWG) and National Institute on Aging–Alzheimer's Association (NIA-AA) revised criteria for Alzheimer's Disease incorporate neuroimaging biomarkers (amyloid PET, tau PET, MRI atrophy) as core diagnostic features, enabling a biological definition of the disease independent of clinical symptoms 11(https://pubmed.ncbi.nlm.nih.gov/39483064/).
For parkinsonian syndromes, the Movement Disorder Society criteria incorporate DaT imaging, MRI findings, and cardiac MIBG scintigraphy to support clinical diagnosis.
Neuroimaging serves as both an enrichment biomarker (identifying eligible participants) and an outcome measure in clinical trials:
The ADNI has established standardized imaging protocols that are now used globally in clinical trials and observational studies 12(https://pubmed.ncbi.nlm.nih.gov/39711072/).
Despite remarkable advances, neuroimaging in neurodegeneration faces several challenges:
Future directions include the development of novel PET tracers for [TDP-43[/entities/[tdp-43[/entities/[tdp-43[/entities/[tdp-43--TEMP--/entities)--FIX--, [alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein--TEMP--/proteins)--FIX--, and specific [neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation--TEMP--/mechanisms)--FIX-- targets; integration of multi-modal imaging with fluid [biomarkers]; and the application of AI to enable earlier and more precise diagnosis 13(https://pubmed.ncbi.nlm.nih.gov/40922096/).
The study of Neuroimaging In Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.